TMCnet News
INNATE PHARMA ANNOUNCES ITS FINANCIAL CALENDAR FOR 2018Innate Pharma announceS ITS FINANCIAL CALENDAR FOR 2018 Marseille, France, December 7, 2017, 7:00 AM CET Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH) today announces its financial calendar for 2018, which is set as follows:
All corporate information on the Company, such as its financial statements or its corporate presentations, is available on the Company's website in the Investors' section (www.innate-pharma.com/en/financials). About Innate Pharma: Innate Pharma S.A. is a clinical-stage biotechnology company dedicated to improving cancer treatment and clinical outcomes for patients through first-in-class therapeutic antibodies that harness the innate immunity. Innate Pharma specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by mobilizing the power of the body's immune system to recognize and kill cancer cells. The Company's broad pipeline includes four first-in-class clinical stage antibodies as well as preclinical candidates and technologies that have the potential to address a broad range of cancer indications ith high unmet medical needs. Innate Pharma has pioneered the discovery and development of checkpoint inhibitors, with a unique expertise and understanding of Natural Killer cell biology. This innovative approach has resulted in major alliances with leaders in the biopharmaceutical industry including AstraZeneca, Bristol-Myers Squibb, Novo Nordisk A/S and Sanofi. Innate Pharma is building the foundations to become a fully-integrated biopharmaceutical company. Based in Marseille, France, Innate Pharma has more than 180 employees and is listed on Euronext Paris. Learn more about Innate Pharma at www.innate-pharma.com Information about Innate Pharma shares:
Disclaimer: This press release contains certain forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Document de Reference prospectus filed with the AMF, which is available on the AMF website (http://www.amf-france.org) or on Innate Pharma's website. This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country. For additional information, please contact:
Attachments: //www.globenewswire.com/NewsRoom/AttachmentNg/c8ca6d73-d549-42ed-ad97-364b6cf93be6 |